Published in IAPAC Mon on February 01, 2005
Understanding diabetes in patients with HIV/AIDS. Diabetol Metab Syndr (2011) 1.13
HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact. AIDS Res Ther (2007) 0.84
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res (2007) 6.89
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med (2011) 4.21
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med (2008) 3.71
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med (2014) 3.48
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol (2008) 3.36
Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr (2002) 3.33
Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med (2004) 2.92
Bone disease and HIV infection. Clin Infect Dis (2005) 2.71
Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis (2014) 2.65
Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation (2008) 2.64
Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis (2006) 2.52
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med (2003) 2.48
Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.37
Specialty training and specialization among physicians who treat HIV/AIDS in the United States. J Gen Intern Med (2002) 2.21
Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis (2010) 2.20
Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis (2003) 2.20
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 2.17
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17
Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis (2004) 2.17
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS (2005) 2.16
A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr (2005) 2.15
Use of a serum beta-glucan assay for diagnosis of HIV-related Pneumocystis jiroveci pneumonia in patients with negative microscopic examination results. Clin Infect Dis (2008) 2.10
Potential savings by reduced CD4 monitoring in stable patients with HIV receiving antiretroviral therapy. JAMA Intern Med (2013) 2.10
Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis (2011) 2.02
Untreated HIV: harmful even at high CD4 cell counts. Lancet (2010) 2.01
Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis (2006) 2.01
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med (2003) 1.98
Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther (2009) 1.97
Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS (2012) 1.90
Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol (2007) 1.90
Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis (2003) 1.89
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Arch Intern Med (2007) 1.84
Body-size dependence of resting energy expenditure can be attributed to nonenergetic homogeneity of fat-free mass. Am J Physiol Endocrinol Metab (2002) 1.82
Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS (2007) 1.78
Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol (2007) 1.77
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med (2014) 1.75
Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis (2001) 1.73
Cost-effectiveness of genotype testing for primary resistance in Brazil. J Acquir Immune Defic Syndr (2015) 1.73
Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr (2010) 1.70
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr (2013) 1.68
Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry (2009) 1.68
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr (2005) 1.67
HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS (2003) 1.66
Editorial commentary: can we break the habit of routine CD4 monitoring in HIV care? Clin Infect Dis (2013) 1.66
Massively parallel pyrosequencing in HIV research. AIDS (2008) 1.63
Independent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women. Am J Clin Nutr (2007) 1.63
Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis (2008) 1.63
Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis (2003) 1.62
The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS (2008) 1.59
Renal safety of tenofovir disoproxil fumarate. AIDS Read (2007) 1.58
Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma. Clin Infect Dis (2004) 1.57
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis (2007) 1.57
Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. J Infect Dis (2006) 1.57
Intermuscular adipose tissue-free skeletal muscle mass: estimation by dual-energy X-ray absorptiometry in adults. J Appl Physiol (1985) (2004) 1.57
Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med (2005) 1.56
A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis (2005) 1.56
Effect of an emergency department HIV testing program on the proportion of emergency department patients who have been tested. Ann Emerg Med (2011) 1.56
Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection. AIDS (2011) 1.55
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. J Antimicrob Chemother (2012) 1.54
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. J Acquir Immune Defic Syndr (2004) 1.48
Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384. Clin Infect Dis (2007) 1.47
HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial. Ann Intern Med (2015) 1.47
Retroviral rebound syndrome with fatal outcome after discontinuation of antiretroviral therapy. Clin Infect Dis (2005) 1.45
The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest (2004) 1.45
Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis (2006) 1.43
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis (2011) 1.40
Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med (2006) 1.40
Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART. AIDS Read (2005) 1.40
Symptomatic and pathophysiologic predictors of hepatitis C virus progression in pediatric patients. Pediatr Infect Dis J (2009) 1.40
Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases. AIDS Read (2008) 1.40
Predicting virologic failure in an HIV clinic. Clin Infect Dis (2010) 1.39
Injectable poly-L-lactic acid for human immunodeficiency virus-associated facial lipoatrophy: cumulative year 2 interim analysis of an open-label study (FACES). Dermatol Surg (2012) 1.39
Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS (2008) 1.38
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses (2005) 1.37
Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr (2007) 1.37
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses (2012) 1.35
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS (2012) 1.34
Body cell mass: model development and validation at the cellular level of body composition. Am J Physiol Endocrinol Metab (2003) 1.33
Physician specialization and antiretroviral therapy for HIV. J Gen Intern Med (2003) 1.31
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS (2007) 1.29
Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. Metabolism (2006) 1.29
Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle. JAMA (2006) 1.27
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr (2007) 1.27
HIV infection and the gastrointestinal tract. AIDS (2005) 1.26
The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana. J Acquir Immune Defic Syndr (2008) 1.26